Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease

作者：Zhao Na; Liu Chia Chen; Qiao Wenhui; Bu Guojun

来源：Biological Psychiatry, 2018, 83(4): 347-357.

DOI：10.1016/j.biopsych.2017.03.003

• Alzheimer's disease
• Amyloid-beta
• Apolipoprotein E
• Low-density lipoprotein receptor family
• Synaptic plasticity
• Tauopathy

Apolipoprotein E (apoE) is a lipid carrier in both the peripheral and the central nervous systems. Lipid-loaded apoE lipoprotein particles bind to several cell surface receptors to support membrane homeostasis and injury repair in the brain. Considering prevalence and relative risk magnitude, the epsilon e4 allele of the APOE gene is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). ApoE4 contributes to AD pathogenesis by modulating multiple pathways, including but not limited to the metabolism, aggregation, and toxicity of amyloid-beta peptide, tauopathy, synaptic plasticity, lipid transport, glucose metabolism, mitochondrial function, vascular integrity, and neuroinflammation. Emerging knowledge on apoE-related pathways in the pathophysiology of AD presents new opportunities for AD therapy. We describe the biochemical and biological features of apoE and apoE receptors in the central nervous system. We also discuss the evidence and mechanisms addressing differential effects of apoE isoforms and the role of apoE receptors in AD pathogenesis, with a particular emphasis on the clinical and preclinical studies related to amyloid-beta pathology. Finally, we summarize the current strategies of AD therapy targeting apoE, and postulate that effective strategies require an apoE isoform-specific approach.

• 出版日期2018-2-15
• 单位厦门大学